/PRNewswire/ – Astellas Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka today announced the promotion of James Robinson as president, Americas Operations, for Astellas US LLC, with responsibility for the company’s operations in North and South America, effective April 1, 2016. Robinson previously served as president, Astellas Pharma US, representing the commercial organization in the United States — a role he assumed in 2013.
Robinson will succeed Masao Yoshida, who is retiring in June 2016.
“As a 10-year veteran of Astellas with more than 20 years of healthcare industry experience, Jim’s commitment to operational and commercial excellence has helped Astellas grow dramatically in the Americas,” said Hatanaka. “His deep experience, skills and strong commitment to operating and leading with the highest sense of ethics and compliance will help Astellas stay focused on our global vision to be on the forefront of healthcare change to turn innovative science into value for patients.”
“Astellas is respected for its unwavering focus on supporting patients. This foundational idea is our compass for continued growth in the Americas,” said Robinson. “We will remain committed to serving patients, pursuing operational excellence within the organization and building Astellas’ presence throughout the Americas.”
Robinson joined Astellas in 2005 as the vice president of health systems, responsible for managed markets, reimbursement strategy, state government affairs and government accounts, and has since held positions of increasing responsibility. In 2011, Robinson was named senior vice president, sales and marketing, leading the US organization responsible for sales, marketing, new product planning, market access and commercial operations.
Robinson began his career at Schering-Plough in 1992 as a sales representative, and held positions of increasing responsibility until he was promoted to vice president of hepatitis sales and managed care in 2003. In this position, he led the largest specialty pharmaceutical sales division within Schering-Plough until he joined Astellas.
He serves as chairman of the Pharmaceutical Research and Manufacturers of America State Committee, is a member of the BioScience council for ChicagoNEXT and serves on the board of directors of MATTER. He is member of The Commercial Club of Chicago and is a graduate of DePaul University.
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.